{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-25-001439","form_type":"8-K","ticker":"HRMY","cik":"0001802665","company_name":"Harmony Biosciences Holdings, Inc.","filed_at":"2025-02-25T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.928820+00:00","generated_at":"2026-05-26T04:52:43.071062+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Harmony Biosciences Q4 2024 net revenue $201.3M, FY $714.7M; guides 2025 $820-860M","bullets":["Q4 2024 net product revenue $201.3M (+20% YoY); FY 2024 net revenue $714.7M (+23% YoY).","Q4 GAAP net income $49.5M ($0.85 diluted EPS); non-GAAP adjusted net income $63.0M ($1.08 diluted EPS).","2025 WAKIX net revenue guidance set at $820M-$860M; on track for potential $1B+ narcolepsy opportunity.","Phase 3 topline for ZYN002 in Fragile X syndrome expected Q3 2025; pitolisant HD trials to start Q4 2025.","Settled first ANDA litigation with Novugen; generic license begins Jan 2030 or earlier under certain conditions."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-25-001439","json":"https://secwatch.observer/filing/0001558370-25-001439.json","markdown":"https://secwatch.observer/filing/0001558370-25-001439.md","text":"https://secwatch.observer/filing/0001558370-25-001439.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1802665/000155837025001439/0001558370-25-001439-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1802665/000155837025001439/hrmy-20250225x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-26T04:52:43.071062+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}